AI summary · may contain errors
In a phase I first-in-human trial in 20 high-risk hereditary PDAC individuals, a six-peptide mutant KRAS vaccine elicited mKRAS-specific T cells in 18/20 (90%) with persistence up to 2 years.
- 2 cited this week
American Association for Cancer Research · Oncology · ISSN 2159-8274, 2159-8290
Rebuilt
AI summary · may contain errors
In a phase I first-in-human trial in 20 high-risk hereditary PDAC individuals, a six-peptide mutant KRAS vaccine elicited mKRAS-specific T cells in 18/20 (90%) with persistence up to 2 years.
AI summary · may contain errors
Targeting RAS with newly available strategies is promising for pancreatic cancer interception because pancreatic precancers also carry KRAS mutations.
AI summary · may contain errors
Blood Cancer United acquired the remaining supply of luveltamab tazevibulin and will keep a compassionate use program for children with a rare form of AML.
AI summary · may contain errors
China approved satricabtagene autoleucel (satri-cel), a CAR T-cell therapy for claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer.
AI summary · may contain errors
Lung tumors in mice can trigger cachexia by directly communicating with neurons to alter eating behavior, and a high-fat diet worsened cachexia rather than reducing it.
AI summary · may contain errors
Transmissible cancer is linked to black splotches on brown bullhead catfish in lakes across New England and Canada, marking the first such finding in fish.
AI summary · may contain errors
Oncoformer predicts cancer development within one year and diagnoses tumors using electronic health records and chest X-rays, trained on Chinese patients and tested on a UK cohort.
AI summary · may contain errors
The FDA approved iberdomide for multiple myeloma using minimal residual disease negativity as the basis, marking a first for the disease.
AI summary · may contain errors
Daraxonrasib, a first-in-class pan-RAS inhibitor, shrank tumors in more than 30% of previously treated RAS-mutant non-small cell lung cancer patients.
AI summary · may contain errors
Anti-B7-H3 ADCs tambotatug pelitecan and risvutatug rezetecan significantly improved overall survival, progression-free survival, and objective response rates versus topotecan in relapsed small-cell lung cancer.
Newest first · last 60 days
AI summary · may contain errors
In newly diagnosed PD-L1–negative advanced nonsquamous NSCLC without targetable alterations, sacituzumab tirumotecan plus pembrolizumab achieved median PFS of 15 months versus 5.7 months with chemotherapy plus pembrolizumab.
AI summary · may contain errors
A genomic atlas of 667 canine tumors maps where dog cancers mirror human disease and where their genetic underpinnings diverge.
AI summary · may contain errors
Anti-CAR antibodies in brain tumor patients are linked to limited durability of chimeric antigen receptor T-cell therapy, undermining the engineered receptor’s persistence.
AI summary · may contain errors
A cfDNA methylation assay detects high-grade intraepithelial neoplasia or esophageal squamous cell carcinoma with 78% standardized sensitivity at 79% specificity in prospective community screening.
AI summary · may contain errors
STP-high intrahepatic cholangiocarcinoma (iCCA) tumors—quantified by a squamous transition potential index—are linked to ASC-like dismal outcomes in about 20-30% of patients.
AI summary · may contain errors
A prebuilt library of T-cell receptors against recurring TP53 mutations enabled personalized autologous T-cell therapy, producing responses lasting 6 to 19 months in early clinical testing.
AI summary · may contain errors
Oncology has remained a top area for National Natural Science Foundation of China (NSFC) grant applications and funded projects across all research fields over the past decade.
AI summary · may contain errors
China’s oncology drug development ecosystem has shifted from rapid pipeline expansion to clinical value-driven innovation across modalities from 2015 to 2025.
AI summary · may contain errors
Single-nucleus analysis of 189 colorectal tumors shows early-onset cancers differ from older-patient tumors in cellular composition, gene signaling, and regulatory RNA expression.
AI summary · may contain errors
In KRASG12C-driven lung adenocarcinoma models with acquired EML4-ALK fusion, EML4-ALK rewires signaling to activate wild-type RAS and bypass KRASG12C inhibition.
AI summary · may contain errors
RMC-8839 selectively reduces viability in KRASG13C-mutant non-small cell lung cancer models, and combining it with docetaxel shows robust anti-proliferative activity in KRASG13C-driven in vitro and in vivo settings.
AI summary · may contain errors
CDK8 inhibitors, including a novel pyridyl imidazole, impair the EWSR1::FLI1 transcriptional program in Ewing sarcoma cells by inducing Mediator trapping on chromatin.
AI summary · may contain errors
CDK8 inhibition releases the muscle differentiation block in fusion-driven alveolar rhabdomyosarcoma, impairing tumor growth and inducing myogenic differentiation in vitro and in vivo.
AI summary · may contain errors
Keith T. Flaherty began a 1-year term as president of the American Association for Cancer Research in April 2026, and discussed advances in cancer research.
AI summary · may contain errors
Eileen M. O’Reilly, MD discusses emerging pancreas cancer treatment strategies, including daraxonrasib combinations and the role of genomic testing, in an expert Q&A.
AI summary · may contain errors
Single-cell profiling of 94 human tumors shows intratumoral aneuploid copy number diversity is linked to higher CNA burden and whole genome doubling, across 62,646 aneuploid cells.
AI summary · may contain errors
Gut pathobionts, especially Bacteroides fragilis, translocate via the gut-liver axis, colonize the liver, and promote hepatocellular carcinoma through bacterial enolase binding hepatocyte vimentin.
AI summary · may contain errors
Autophagy-driven secretion of intracellular antigens (SICAs) in a spontaneous hepatocellular carcinoma model generates ALDH1L1 autoantibodies that form immune complexes and recruit neutrophils to drive tumor progression.
Journals this month
Topics moving, week to 17 Nov 2026
By field